100% agree with your sentinent regarding Equity Story and their...

First 24 Last

Share
Profile

Follow
JT1401

12 Posts.

2

28/02/18

13:47

Post #: 31415545
Share

Originally posted by 1ronnie ↑

I can understand them making the Nestle announcement in conjunction with the launch , its a great endorsement for a market entrant absolutely. But it would be a greater endorsement has Nestle themselves come out to endorse the product.

"Nestlé Jamaica deployed the Ohm by Digicel system in their primary Kingston facility,
a combination office and factory. Following a successful first deployment, Nestle has now expanded upon their initial installation, and is expected to deploy further systems in the region"

I take it that the region means in the vicinity of Jamaica and the Caribbean.

See how different that is to what Equity Story presented as "into their network of factories globally"

Equity Story believes this has presented an excellent time to enter the Buddy Platform story if you are not already invested in the company. Buddy has signed deals with Ingram Micro, Telstra (have they??), etc... throughout the world and today announced a deal with Nestle after successful trials to incorporate the Buddy Ohm platform into their network of factories globally (Nestle has 447 factories and operates in 194 countries employing approximately 390,000 staff).

Equity Story should be more careful in their wordings. BUD management has not yet learnt from past mistakes to accentuate their announcement and get everyone excited to spruik the sp (GSW did that to their peril). It has so far been deployed at one facility and there is expectation (yes expectation) that it would be deployed in the region. Maybe BUD holders want to read something bigger than what it is at present.

Expand

100% agree with your sentinent regarding Equity Story and their wordings. While the use of “imminent” by BUD previously has caused all sorts of issues already covered; I have and see no issue with the wording in this Nestle announcement. While it would have been great if they had figures etc to provide in this announcement; still had to be disclosed to market since they announced it at MWC.

BUD Price at posting: 20.0¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 111 more messages in this thread...

First 24 Last

Add BUD (ASX) to my watchlist

100% agree with your sentinent regarding Equity Story and their...

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News